AN2 Therapeutics (ANTX) EBT (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly EBT of -$17.3 million for Q1 2026, down 55.71% year-over-year from -$39.2 million in Q1 2025, and down 99.07% quarter-over-quarter from -$8.7 million in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) EBT (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported EBT for 6 consecutive years, with -$17.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 55.71% year-over-year to -$17.3 million; the TTM figure through Mar 2026 stood at -$42.4 million (up 9.63% YoY), while the FY2025 annual figure was -$35.3 million, up 67.7% from the prior year.
- EBT eased to -$17.3 million in Q1 2026 per ANTX's latest filing, from -$8.7 million in the prior quarter.
- Across five years, EBT topped out at -$6.6 million in Q2 2025 and bottomed at -$60.6 million in Q4 2023.
- Historically, EBT has averaged -$19.3 million across 5 years, with a median of -$15.0 million in 2024.
- Annual changes were most pronounced in 2022 — EBT sank 991.8% — and 2024, when it jumped 87.05%.
- AN2 Therapeutics' EBT stood at -$11.9 million in 2022, then plunged by 410.98% to -$60.6 million in 2023, then soared by 87.05% to -$7.9 million in 2024, then declined by 10.99% to -$8.7 million in 2025, then sank by 99.07% to -$17.3 million in 2026.
- Business Quant data shows ANTX's EBT at -$17.3 million in Q1 2026, -$8.7 million in Q4 2025, and -$9.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -11.37 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | -8.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.18 Mn |
| Mar 31, 2026 | -10.03 Mn |
| Dec 31, 2025 | -8.71 Mn |
| Sep 30, 2025 | -9.35 Mn |
| Jun 30, 2025 | -6.46 Mn |
| Mar 31, 2025 | -10.65 Mn |
| Dec 31, 2024 | -7.52 Mn |
| Sep 30, 2024 | -12.75 Mn |
| Jun 30, 2024 | -14.44 Mn |
| Mar 31, 2024 | -16.62 Mn |
| Dec 31, 2023 | -18.82 Mn |
| Sep 30, 2023 | -18.18 Mn |
| Jun 30, 2023 | -16.60 Mn |
| Mar 31, 2023 | -16.04 Mn |
| Dec 31, 2022 | -11.85 Mn |
| Sep 30, 2022 | -11.30 Mn |
| Jun 30, 2022 | -10.11 Mn |
| Mar 31, 2022 | -7.66 Mn |
| Dec 31, 2021 | -7.57 Mn |
| Sep 30, 2021 | -6.91 Mn |